№ files_lp_3_process_9_47461
File format: docx
Character count: 4340
File size: 64 KB
Structured table presenting the detailed search strategy and results for literature on hepatocellular carcinoma surveillance programs across multiple databases.
Year:
1946–Present
Region / Database:
Cochrane [Wiley], Embase [Ovid], Medline [OVID]
Subject:
Hepatocellular carcinoma, liver cancer
Document type:
Supplementary table
Organization / Source:
Cochrane, Embase, Medline
Language:
English
Population:
Adults, humans
Methods:
Search strategy, program evaluation, reminder systems, outreach programs
Duplicates removed:
Yes
Data limits:
English language, human studies
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
University of Washington Medical Center
Topic:
Diagnostic Ultrasound Protocol
Document Type:
Protocol
Organization:
University of Washington Medical Center
Author:
Unknown
Target Audience:
Medical Professionals
Period of validity:
Not specified
Approval Date:
10/25/2021
Date of changes:
10/25/2021
Context:
A medical protocol detailing diagnostic ultrasound procedures for screening of liver conditions including Hepatocellular Carcinoma (HCC) and Right Upper Quadrant (RUQ) evaluation at the University of Washington Medical Center.
Year:
2022
Region / city:
Nanjing
Topic:
Hepatocellular Carcinoma, Gut Microbiota, Immunology
Document type:
Supplementary Materials
Organization / institution:
Nanjing Medical University
Author:
Chupeng Hu, Bingqing Xu, Yun Chen
Target audience:
Researchers, scientists, medical professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2010-2024
Region / city:
Asia-Pacific
Subject:
Hepatology
Document Type:
Clinical Practice Guidelines
Organization / Institution:
Asian Pacific Association for the Study of the Liver (APASL)
Author:
APASL
Target Audience:
Healthcare professionals
Period of validity:
2010-2024
Date of approval:
2010
Date of revisions:
2024
Context:
Collection of clinical practice guidelines and consensus statements issued by the Asian Pacific Association for the Study of the Liver on various hepatological conditions, including hepatocellular carcinoma, hepatitis B and C, liver transplantation, and metabolic diseases.
Year:
2023
Region / City:
Singapore
Theme:
Hepatocellular carcinoma, Surgical resection
Document type:
Meta-analysis
Author:
Aaron JL Lee, Andrew GR Wu, Kuo Chao Yew, Vishal G Shelat
Target audience:
Medical professionals, Researchers
Period of validity:
Not specified
Approval date:
February 1, 2023
Date of changes:
Not specified
Year:
2024
Region / City:
Biobío, Chile
Topic:
Hepatocellular carcinoma, prognosis prediction, imaging techniques
Document Type:
Letter to the Editor
Organization / Institution:
World Journal of Gastrointestinal Surgery
Author:
Cristian Lindner
Target Audience:
Medical professionals, researchers in oncology and radiology
Effective Period:
2024
Approval Date:
August 28, 2024
Date of Revisions:
August 19, 2024
Keywords:
Hepatocellular carcinoma, Radiofrequency ablation, Transcatheter arterial chemoembolization, Prognosis, Magnetic resonance imaging, Radiomics, Artificial intelligence
DOI:
https://dx.doi.org/10.4240/wjgs.v16.i10.0000
URL:
https://www.wjgnet.com/1948-9366/full/v16/i10/0000.htm
Core Tip:
Emerging imaging techniques, particularly multiparametric magnetic resonance imaging and radiomics, enhance prognostic models for hepatocellular carcinoma (HCC) treated with radiofrequency ablation and transarterial chemoembolization. Incorporating advanced imaging features alongside clinical factors refines prediction accuracy, aiding personalized treatment and improving patient outcomes.
Year:
2024
Region / City:
Bamako, Mali
Subject:
Hepatocellular carcinoma, liver diseases
Document Type:
Research study
Institution:
Gabriel Touré University Hospital
Author:
Not specified
Target Audience:
Medical professionals, researchers
Period of validity:
February 2024 - January 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / City:
Nanfang Hospital
Theme:
Hepatology, Cancer Diagnosis
Document Type:
Scientific Methodology
Institution:
Nanfang Hospital
Author:
Unspecified
Target Audience:
Medical Professionals, Researchers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
This document presents the diagnostic criteria for cirrhosis and hepatocellular carcinoma, including imaging techniques and laboratory results, based on a multi-center study with radiomics and deep learning features for prediction models.
Journal:
World Journal of Gastrointestinal Oncology
Manuscript Number:
80135
Manuscript Type:
Review
Authors:
Ying-Zhe Luo; Hong Zhu
Author Affiliations:
Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Corresponding Author:
Hong Zhu
Funding:
The Key Research Projects of Science and Technology of Sichuan Province (No. 2022YFS0189)
Received:
September 18, 2022
Revised:
February 11, 2023
Accepted:
February 27, 2023
Published Online:
March 15, 2023
Volume and Issue:
Volume 15, Issue 3
Pages:
405-424
DOI:
10.4251/wjgo.v15.i3.405
Publisher:
Baishideng Publishing Group Inc.
Keywords:
Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine
Subject Area:
Oncology; Hepatology; Cancer Immunotherapy
Geographic Context:
Global epidemiology with reference to East and South-East Asia, United States, and Europe
Year:
2026
Region / City:
Honolulu, HI, USA; Ann Arbor, MI, USA
Topic:
Hepatocellular carcinoma genetics
Document type:
Research article
Institution:
University of Hawaii Cancer Center; University of Michigan
Authors:
Kumardeep Chaudhary, Olivier B Poirion, Liangqun Lu, Sijia Huang, Travers Ching, Lana X Garmire
Funding:
NIEHS K01ES025434, P20 COBRE GM103457, NICHD R01 HD084633, NLM R01LM012373, Hawaii Community Foundation 14ADVC-64566
Target audience:
Biomedical researchers, oncologists, bioinformaticians
Methods:
Multi-modal meta-analysis, mutation profiling, Kaplan-Meier survival analysis, bipartite graph analysis
Sample size:
1494 HCC samples across 6 cohorts
Key findings:
Associations of consensus driver genes with phenotypes, miR expression, CNV, and overall survival
Supplementary materials:
Figures S1–S8, Table S1, File S1
Document type of source:
Peer-reviewed scientific publication
Year:
2022
Country:
Nigeria
Organization:
Society for Gastroenterology & Hepatology in Nigeria (SOGHIN)
Document type:
Clinical practice guidelines
Edition:
Second edition
Subject:
Hepatocellular carcinoma management
Medical field:
Gastroenterology and hepatology
Target audience:
Medical practitioners and healthcare professionals
Guidelines committee:
Prof. Dennis A. Ndububa; Prof. Fatimah B. Abdulkareem; Prof. Shettima K. Mustapha; Dr. Christopher N. Ekwunife; Prof. Casimir E. Omuemu
Institutions represented:
Obafemi Awolowo University Teaching Hospitals Complex; Lagos University Teaching Hospital; Ahmadu Bello University Teaching Hospital; Federal Medical Centre Owerri; University of Benin Teaching Hospital
Geographical focus:
Nigeria and sub-Saharan Africa
Topics covered:
Epidemiology of hepatocellular carcinoma, surveillance strategies, diagnostic confirmation, staging systems, treatment modalities, and prevention
Disease focus:
Hepatocellular carcinoma
Associated conditions:
Chronic hepatitis B, hepatitis C, cirrhosis, non-alcoholic fatty liver disease
Publication context:
Resource-constrained healthcare settings
Year:
2023
Region / City:
Guangzhou, China
Field:
Traditional Chinese Medicine, Oncology
Document Type:
Cover Letter and Response to Reviewers
Institution:
The First Affiliated Hospital, Sun Yat-sen University
Author:
Shijun Zhang
Target Audience:
Journal editors and peer reviewers
Manuscript ID:
TMR2023A0227001
Research Focus:
Exosome-mediated invasion and metastasis in HCC under spleen-deficient conditions
Methods:
Nanoparticle tracking analysis, transmission electron microscopy, bioluminescence imaging
Figures Included:
Figures 1-4, Table 1
Key Findings:
Exosomes promote HCC cell invasion and metastasis; size differences observed in SD-HCC vs HCC groups
Submission Status:
Revised manuscript with highlighted modifications in red
Correspondence Email:
[email protected]
Single-sentence description:
Peer-reviewed correspondence detailing authors’ point-by-point responses to reviewer comments on an experimental study investigating the role of exosomes in hepatocellular carcinoma under spleen-deficient conditions.
Year:
2022
Region / City:
Oulu, Vaasa, Jyväskylä, Finland; Solna, Sweden
Topic:
Hepatocellular carcinoma, Prognostic markers
Document type:
Research Article
Institution:
Oulu University Hospital, Karolinska Institutet
Authors:
Niklas Sarelin, Valtteri Kairaluoma, Juha Saarnio, Joonas H. Kauppila, Jan Böhm, Heikki Huhta, Juha P. Väyrynen, Olli Helminen
Target audience:
Medical researchers, oncologists, pathologists
Period of validity:
N/A
Approval date:
2022
Modification date:
N/A
Year:
2023
Region / city:
Chongqing, P.R. China
Subject:
Hepatocellular carcinoma, Inflammatory biomarkers, Prognostic indicators
Document type:
Research article
Organization:
Second Affiliated Hospital of Chongqing Medical University
Author:
Jun-Yu Zhou, Jia-Qian Gao, Qi He, Kai Lei, Wen-Feng Zhang, Yue Li
Target audience:
Medical professionals, Researchers in oncology and hepatology
Period of validity:
2021-2023
Approval date:
2023
Date of changes:
N/A
Year:
2021
Journal:
World Journal of Clinical Cases
Volume:
9
Issue:
36
Pages:
11495–11503
DOI:
10.12998/wjcc.v9.i36.11495
Publisher:
Baishideng Publishing Group Inc.
Document Type:
Case report
Academic Field:
Clinical medicine; Hepatic surgery; Oncology
Medical Topic:
Hepatocellular carcinoma with tumor thrombosis in inferior vena cava
Authors:
Zun-Yi Zhang; Er-Lei Zhang; Bi-Xiang Zhang; Wei Zhang
Affiliation:
Research Laboratory and Hepatic Surgery Center, Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Institution Location:
Wuhan, Hubei Province, China
Corresponding Author:
Wei Zhang
Submission Date:
August 19, 2021
Revision Date:
September 25, 2021
Acceptance Date:
November 14, 2021
Online Publication Date:
December 26, 2021
Funding:
National Natural Science Foundation of China (No. 81802767; No. 81860117)
Patient Characteristics:
47-year-old woman with chronic hepatitis B and hepatocellular carcinoma
Clinical Intervention:
Right major hepatectomy with tumor thrombectomy under cardiopulmonary bypass followed by sorafenib therapy
Follow-up Period:
11 months
Outcome:
No recurrence detected during follow-up
Year:
2015
Region / City:
Istanbul, Turkey
Theme:
Hepatology, Hepatitis B, Hepatocellular carcinoma
Document type:
Review article
Organization / Institution:
Koç University Hospital
Author:
Bulent Baran
Target audience:
Medical professionals, researchers in hepatology
Period of action:
Ongoing
Approval date:
June 18, 2015
Revision date:
May 6, 2015
Peer review date:
February 2, 2015
Published online:
June 18, 2015
Version:
4.4.0.0
Protocol Posting Date:
June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2022
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Note:
Accreditation Requirements
Year:
2021
Region / City:
Global
Theme:
Oncology, Breast Cancer
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Medical professionals, pathologists
Period of Validity:
From March 2022
Date of Approval:
June 2021
Date of Changes:
June 2021
Year:
2024
Region / City:
Not specified
Subject:
Pathology, Oncology
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Uma G. Krishnamurti, MD, PhD; Kimberly H. Allison, MD; Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Pathologists, Medical Institutions
Period of Validity:
March 2025
Approval Date:
Not specified
Date of Last Change:
June 2024
Version:
4.2.0.1
Protocol Posting Date:
June 2022
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2022
For accreditation purposes:
Surgical resection, including esophagectomy and esophagogastrectomy; Epithelial tumors of the esophagus, and esophagogastric junction with tumor involvement of no more than 2 cm into the proximal stomach.
Authors:
Lawrence J. Burgart, MD; William V. Chopp, MD; Dhanpat Jain, MD
Synoptic Reporting:
Core and conditional data elements must be reported in a synoptic format for accreditation.
Case Summary:
Esophagus
Histologic Type:
Adenocarcinoma, Squamous cell carcinoma, Neuroendocrine carcinoma, among others.
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology
Version:
4.2.1.0
Protocol Posting Date:
June 2025
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2026
Year:
2025
Region / City:
Not specified
Subject:
Renal cell carcinoma, nephrectomy, tumor classification
Document Type:
Protocol
Institution:
CAP (College of American Pathologists)
Author:
Paari Murugan, MD, FCAP*, Robert W. Allan, MD, FCAP*, Lara R. Harik, MD, FCAP*
Target Audience:
Pathologists, medical professionals involved in cancer diagnostics
Effective Period:
March 2026 onward
Approval Date:
June 2025
Revision Date:
Not specified